Heart FailureHUMVEENCT03189368
Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling
An observational study of Heart Failure, run by National and Kapodistrian University of Athens at 1 site in Greece.
Trial summary
To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- Activation of multi-site pacing capability on CRT devices
- Type of treatment
- Medical device
- How many people
- 80 participants
- Where
- 1 siteGreece
- Study dates
- 18 Sep 2017to 1 Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Systolic heart failure with an ejection fraction of 35% or less, at NYHA functional class of II or worse, and a QRS displaying either LBBB morphology and >120msec or non-LBBB morphology and >150msec.
Who may be able to join
- Adult (>18 years of age), consenting patients
- Any cardiomyopathy type and
- An existing I/IIa indication for a CRT-D device
Who cannot join
- Those with a class IIb CRT indication
- Those where thresholds of <3.5V@0.5msec cannot be achieved in at least two dipoles of the left pacing electrode
- Those where no dipole with a distance between poles of 30mm can be detected
- Those with >2/4 (moderate to severe - severe) mitral/aortic insufficiency, rendering noninvasive VAC calculation unreliable.
- Finally, contraindication to receiving intravenous paramagnetic contrast (gadolinium) will also constitute grounds for exclusion.
Trial locations and contacts
1 site in 1 country.
Greece1 site
First Department of Cardiology, Hippokration General Hospital
Athens, Attica, 11527
About this study
To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart
Read the detailed description
Given that the main function of the cardiovascular system is to provide sufficient blood supply to tissues in order to ensure their normal and effective function, combined with the most efficient possible use of energy produced by ATP degradation, there has been a keen interest in elucidating the interplay between heart and vessels, critically affecting both.
In order to achieve these goals, it is thought that in healthy humans the cardiovascular system as a unity operates at a unique combination of parameters (arterial elastance, heart rate and left ventricular end systolic elastance) so as to:
- Maximize stroke work (SW) for a given left ventricular contractility. This is related to the fact that adequate tissue perfusion is dependent both on stroke volume and on pressure and in fluid dynamics W=∆P×∆V (thus maximizing SW leads to optimal perfusion), OR
- Optimize energy efficiency of the heart, in terms of energy transferred to the arterial bed to total mechanical energy.
Ventriculoarterial coupling (VAC) is a composite parameter, defined as the ratio of arterial elastance (Ea) to end systolic left ventricular elastance (Ees). Thus: VAC=Ea/Ees . It is a fundamental property of the cardiovascular system, integrating and assessing the interaction of all individual parameters of the ventricle (pump) and the arterial tree (afterload). Furthermore, VAC may assess both whether SW produced is maximal for a given contractility of the left ventricle (condition for maximization: VAC=1) and whether mechanical efficiency of the ventricle is optimal (optimization condition: VAC=0.5-0.7). Consequently, simultaneous optimization is not possible, and the cardiovascular system operates either at maximal output (as in healthy individuals at rest) or at optimal efficiency (healthy individuals at exercise). Multi-site pacing (MSP) of the left ventricle is a recently introduced technique with excellent studies' findings concerning echocardiographic parameters of ventricular function. Recently, the MultiPoint Pacing (MPP) IDE study showed that a specific choice of electrical dipole for the first left ventricular pulse and a close to simultaneous application of the two left ventricular pulses achieves a very high percent of clinical response (87%), with excellent patient safety. Subsequent studies confirmed these findings, reporting even higher NYHA response rates (95% vs 78% for conventional cardiac resynchronization therapy - CRT).
The underlying rationale lies in the better approximation of the normal sequence of left ventricular activation, through use of two, instead of a single, pulses. According to trial results, one can achieve, compared to conventional CRT, improved coordination between left ventricular segments, improved cardiac output and, possibly, tissue perfusion, and potentially reduction of arrhythmia propensity (mechanism similar to that of CRT). Thus, it would be interesting to study whether these can be independently confirmed by changes in VAC values. In heart failure, VAC values increase considerably due to increases in Ea as a result of the feedback loop regarding pressure (but not volume) maintenance. As a consequence, any reduction would move them closed to both 1 and the 0.5-0.7 area, yielding improvement in both SW maximization and efficiency optimization.
However, there are objective difficulties in achieving lege artis MSP (according to MPP-IDE study standards) given that two prerequisites must be met: 1. Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used), 2. Nearly simultaneous (Δt=5msec) left ventricular pulses and 3. Threshold of ≤3.5V@0.5msec.
Moreover, the first pulse should, ideally, be directed to the most delayed, compared to the normal activation sequence, viable myocardial segment, a feat not always possible due to electrode placing constraints. Obviously, presence of scar could alter the course and shape of the activation front and thus diminish its effects (similar to issues already discussed in the case of CRT).
Objective:
To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart
Hypothesis:
VAC values are improved (shift closer to unity/0.5-0.7 area) and work/efficiency increase with patients on MSP as compared to CRT pacing.
- Conditions
- Heart Failure
- Being tested
- Activation of multi-site pacing capability on CRT devices
- Keywords
- Cardiac Resynchronization Therapy, Multi-site Pacing, Ventriculoarterial Coupling, Energy Efficiency
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Activation of multi-site pacing capability on CRT devicesDevice
Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed "sculpting" of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.
Programming features:
- Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used)
- Nearly simultaneous (Δt=5msec) second left ventricular pulse and
- Threshold of ≤3.5V@0.5msec
| Study group | Role | What they receive |
|---|---|---|
| Heart failure patients eligible for CRT | Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.
Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired. Receives: Device: Activation of multi-site pacing capability on CRT devices |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of ventriculoarterial coupling
Ventriculoarterial coupling value shifts closer to 1
Measured: 6 months for each intervention (conventional CRT - MPP)
Improvement of energy efficiency
Energy efficiency improvement will be assessed by means of ventriculoarterial coupling value shifts closer to 0.7
Measured: 6 months for each intervention (conventional CRT - MPP)
Secondary outcomes (2)
Improvement in renal function
Creatinine clearance (Cockcroft-Gault formula) increases
Measured: 6 months for each intervention (conventional CRT - MPP)
Improvement in percent maximal stroke work
Calculated through use of ventriculoarterial coupling
Measured: 6 months for each intervention (conventional CRT - MPP)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2017
- Study start18 Sep 2017
- Primary completion1 Sep 2020
- Study completion1 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by National and Kapodistrian University of AthensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- National and Kapodistrian University of Athens
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Polychronis Dilaveris, National and Kapodistrian University of Athens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03189368
- Sponsor's protocol ID
- HippoCT1
- Acronym
- HUMVEE
- Status last verified
- Sep 2020
- First submitted
- 12 Jun 2017
- Last updated
- 11 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Chrysohoou C, Dilaveris P, Antoniou CK, Skiadas I, Konstantinou K, Gatzoulis K, Kallikazaros I, Tousoulis D. Heart failure study of multipoint pacing effects on ventriculoarterial coupling: Rationale and design of the HUMVEE trial. Ann Noninvasive Electrocardiol. 2018 May;23(3):e12510. doi: 10.1111/anec.12510. Epub 2017 Oct 15.
PubMed 29034563
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling
- ClinicalTrials.gov ID
- NCT03189368
- Acronym / sponsor ID
- HUMVEE / HippoCT1
- Conditions
- Heart Failure
- Keywords
- Cardiac Resynchronization Therapy, Multi-site Pacing, Ventriculoarterial Coupling, Energy Efficiency
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- National and Kapodistrian University of AthensUniversity, hospital or other
- Study start
- 18 Sep 2017 (actual)
- Primary completion
- 1 Sep 2020 (actual)
- Study completion
- 1 Sep 2020 (actual)
- First posted
- 16 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart
Detailed description
Given that the main function of the cardiovascular system is to provide sufficient blood supply to tissues in order to ensure their normal and effective function, combined with the most efficient possible use of energy produced by ATP degradation, there has been a keen interest in elucidating the interplay between heart and vessels, critically affecting both.
In order to achieve these goals, it is thought that in healthy humans the cardiovascular system as a unity operates at a unique combination of parameters (arterial elastance, heart rate and left ventricular end systolic elastance) so as to:
- Maximize stroke work (SW) for a given left ventricular contractility. This is related to the fact that adequate tissue perfusion is dependent both on stroke volume and on pressure and in fluid dynamics W=∆P×∆V (thus maximizing SW leads to optimal perfusion), OR
- Optimize energy efficiency of the heart, in terms of energy transferred to the arterial bed to total mechanical energy.
Ventriculoarterial coupling (VAC) is a composite parameter, defined as the ratio of arterial elastance (Ea) to end systolic left ventricular elastance (Ees). Thus: VAC=Ea/Ees . It is a fundamental property of the cardiovascular system, integrating and assessing the interaction of all individual parameters of the ventricle (pump) and the arterial tree (afterload). Furthermore, VAC may assess both whether SW produced is maximal for a given contractility of the left ventricle (condition for maximization: VAC=1) and whether mechanical efficiency of the ventricle is optimal (optimization condition: VAC=0.5-0.7). Consequently, simultaneous optimization is not possible, and the cardiovascular system operates either at maximal output (as in healthy individuals at rest) or at optimal efficiency (healthy individuals at exercise). Multi-site pacing (MSP) of the left ventricle is a recently introduced technique with excellent studies' findings concerning echocardiographic parameters of ventricular function. Recently, the MultiPoint Pacing (MPP) IDE study showed that a specific choice of electrical dipole for the first left ventricular pulse and a close to simultaneous application of the two left ventricular pulses achieves a very high percent of clinical response (87%), with excellent patient safety. Subsequent studies confirmed these findings, reporting even higher NYHA response rates (95% vs 78% for conventional cardiac resynchronization therapy - CRT).
The underlying rationale lies in the better approximation of the normal sequence of left ventricular activation, through use of two, instead of a single, pulses. According to trial results, one can achieve, compared to conventional CRT, improved coordination between left ventricular segments, improved cardiac output and, possibly, tissue perfusion, and potentially reduction of arrhythmia propensity (mechanism similar to that of CRT). Thus, it would be interesting to study whether these can be independently confirmed by changes in VAC values. In heart failure, VAC values increase considerably due to increases in Ea as a result of the feedback loop regarding pressure (but not volume) maintenance. As a consequence, any reduction would move them closed to both 1 and the 0.5-0.7 area, yielding improvement in both SW maximization and efficiency optimization.
However, there are objective difficulties in achieving lege artis MSP (according to MPP-IDE study standards) given that two prerequisites must be met: 1. Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used), 2. Nearly simultaneous (Δt=5msec) left ventricular pulses and 3. Threshold of ≤3.5V@0.5msec.
Moreover, the first pulse should, ideally, be directed to the most delayed, compared to the normal activation sequence, viable myocardial segment, a feat not always possible due to electrode placing constraints. Obviously, presence of scar could alter the course and shape of the activation front and thus diminish its effects (similar to issues already discussed in the case of CRT).
Objective:
To perform a comparative study of multi-site left ventricular pacing and cardiac resynchronization therapy effects on ventriculoarterial coupling and energy efficiency of the failing heart
Hypothesis:
VAC values are improved (shift closer to unity/0.5-0.7 area) and work/efficiency increase with patients on MSP as compared to CRT pacing.
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Heart failure patients eligible for CRT | – | Device: Activation of multi-site pacing capability on CRT devicesAdult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral. Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Systolic heart failure with an ejection fraction of 35% or less, at NYHA functional class of II or worse, and a QRS displaying either LBBB morphology and >120msec or non-LBBB morphology and >150msec.
Key inclusion criteria (3 listed)
- Adult (>18 years of age), consenting patients
- Any cardiomyopathy type and
- An existing I/IIa indication for a CRT-D device
Key exclusion criteria (5 listed)
- Those with a class IIb CRT indication
- Those where thresholds of <3.5V@0.5msec cannot be achieved in at least two dipoles of the left pacing electrode
- Those where no dipole with a distance between poles of 30mm can be detected
- Those with >2/4 (moderate to severe - severe) mitral/aortic insufficiency, rendering noninvasive VAC calculation unreliable.
- Finally, contraindication to receiving intravenous paramagnetic contrast (gadolinium) will also constitute grounds for exclusion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Activation of multi-site pacing capability on CRT devicesInstead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed "sculpting" of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters. Programming features: * Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used) * Nearly simultaneous (Δt=5msec) second left ventricular pulse and * Threshold of ≤3.5V@0.5msec | Device | Heart failure patients eligible for CRT |
Primary outcome
Improvement of ventriculoarterial coupling
Time frame: 6 months for each intervention (conventional CRT - MPP)
Ventriculoarterial coupling value shifts closer to 1
Improvement of energy efficiency
Time frame: 6 months for each intervention (conventional CRT - MPP)
Energy efficiency improvement will be assessed by means of ventriculoarterial coupling value shifts closer to 0.7
2 secondary outcomes
Improvement in renal function
Time frame: 6 months for each intervention (conventional CRT - MPP)
Improvement in percent maximal stroke work
Time frame: 6 months for each intervention (conventional CRT - MPP)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2020.
- Derived from this study: PubMed 29034563Chrysohoou C, Dilaveris P, Antoniou CK, Skiadas I, Konstantinou K, Gatzoulis K, Kallikazaros I, Tousoulis D. Heart failure study of multipoint pacing effects on ventriculoarterial coupling: Rationale and design of the HUMVEE trial. Ann Noninvasive Electrocardiol. 2018 May;23(3):e12510. doi: 10.1111/anec.12510. Epub 2017 Oct 15.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
Chronic Heart Failure, CKD Stage 3
Not yet recruiting
SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome
Cardiovascular-kidney-metabolic Syndrome, Diabete Type 2
Not yet recruiting
Notification Of High-Risk Veterans for Access to Heart Failure Prevention
Heart Failure
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
Mitral Regurgitation Functional, Heart Failure With Reduced Ejection Fraction (HFrEF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by National and Kapodistrian University of Athens at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of ventriculoarterial coupling (time frame: 6 months for each intervention (conventional CRT - MPP)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03189368, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2020.